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Abstract
Background: We systematically reviewed observational studies of early mortality post-antiretroviral therapy (ART) initiation
in low- and middle-income countries (LMIC) in Asia, Africa, and Central and South America, as defined by the World Bank, to
summarize what is known.
Methods and Findings: Studies published in English between January 1996 and December 2010 were searched in Medline
and EMBASE. Three independent reviewers examined studies of mortality within one year post-ART. An article was included
if the study was conducted in a LMIC, participants were initiating ART in a non-clinical trial setting and were $15 years. Fifty
studies were included; 38 (76%) from sub-Saharan Africa (SSA), 5 (10%) from Asia, 2 (4%) from the Americas, and 5 (10%)
were multi-regional. Median follow-up time and pre-ART CD4 cell count ranged from 3–55 months and 11–192 cells/mm
3,
respectively. Loss-to-follow-up, reported in 40 (80%) studies, ranged from 0.3%–27%. Overall, SSA had the highest pooled
12-month mortality probability of 0.17 (95% CI 0.11–0.24) versus 0.11 (95% CI 0.10–0.13) for Asia, and 0.07 (95% CI 0.007–
0.20) for the Americas. Of 14 (28%) studies reporting cause-specific mortality, tuberculosis (TB) (5%–44%), wasting (5%–
53%), advanced HIV (20%–37%), and chronic diarrhea (10%–25%) were most common. Independent factors associated with
early mortality in 30 (60%) studies included: low baseline CD4 cell count, male sex, advanced World Health Organization
clinical stage, low body mass index, anemia, age greater than 40 years, and pre-ART quantitative HIV RNA.
Conclusions: Significant heterogeneity in outcomes and in methods of reporting outcomes exist among published studies
evaluating mortality in the first year after ART initiation in LMIC. Early mortality rates are highest in SSA, and opportunistic
illnesses such as TB and wasting syndrome are the most common reported causes of death. Strategies addressing
modifiable risk factors associated with early death are urgently needed.
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Introduction
Ninety-five percent of the estimated 33.4 million HIV-infected
adults live in low- and middle-income countries (LMIC) and
approximately 7.1 million of these individuals have advanced HIV
and are in need of antiretroviral treatment (ART) [1]. A massive
global effort to provide ART is underway and if current trends
continue, by 2015, 8 million HIV-infected persons will be
receiving ART. ART has dramatically reduced morbidity and
mortality worldwide [2–4]; however a .3-fold increased rate of
mortality within the first 12 months post-ART initiation has been
observed in LMIC compared to high-income countries [5].
A summary of cohorts of sub-Saharan African (SSA) settings
previously identified a mortality estimate of 8%–26% at 12
months post-ART initiation [6]. However, this review did not
include studies from Asia or the Americas, where substantial
numbers of patients are also initiating ART. Furthermore, while
it is clear that starting ART at higher CD4 counts will reduce
mortality, many patients at ART clinics in LMIC continue to
present with advanced HIV. Therefore, the objective of our study
was to systematically review observational cohort data on early
mortality, which we defined as death within 12 months post-ART
initiation among persons in LMIC. We specifically wanted to
measure the early mortality post-ART initiation in different
regions, assess the relative causes of early mortality, and
determine risk factors for mortality in these settings; such data
are needed to inform global programs and global priorities for
HIV care and treatment.
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28691Methods
Search strategy and selection criteria
We searched Medline and EMBASE databases for articles
published between January 1996, (when combination ART was
heralded) and December 2010. Keywords used for the search
strategy included ‘‘developing countries’’, ‘‘Africa’’, ‘‘South
America’’, ‘‘Asia’’, ‘‘developing country’’, ‘‘mortality’’, ‘‘death’’,
‘‘deaths’’, ‘‘antiretroviral therapy’’, ‘‘highly active’’, ‘‘haart’’, ‘‘anti-
retrovirals’’, ‘‘antiretrovirals’’, ‘‘antiretroviral’’, ’’anti retroviral’’,
‘‘highly active antiretroviral therapy’’ (see table S1 for exact
search strategy used). We limited the search to human studies and
articles published in English. A total of 1776 potentially relevant
citations were identified and compiled from both electronic
databases; 875 articles remained after elimination of duplicates.
Three reviewers (NG, GN, AC) screened titles and abstracts to
capture potentially relevant studies and one reviewer (AG)
resolved any discrepancies between them. Studies were included
if they met the following criteria: a) study was in a LMIC as
defined by the World Bank in 2008 {http://data.worldbank.org/
about/country-classifications}, b) age of the participants was $15
years, c) participants were ART naı ¨ve at baseline or the authors
gave data separately for naı ¨ve and non-naı ¨ve, d) mortality was
reported within the first year after ART initiation and, e) size of
the cohort was .50 participants. We excluded editorials, case
reports, abstracts, letters, reviews, clinical trials, studies including
only children and studies that focused on deaths due to a specific
opportunistic infection. Full text review was completed by three
independent reviewers (GN, WY and NG). Additional data were
not obtained from study authors.
Data extraction and analysis
For studies that met the inclusion criteria, data were extracted
and results tabulated. The primary objective of the study was to
measure early mortality post-ART initiation in different LMIC
regions. The defined regions were LMIC in SSA, Asia, the
Americas (South America, Central America and the Caribbean),
and multi-regional (Africa, Asia and the Americas). We reported
mortality data using the methods presented in each article
including probability of survival using Kaplan-Meier curves;
incidence rates; and proportions. Meta-analysis was done to
estimate an overall and also a combined estimate of mortality rate
within each region. Heterogeneity between the studies was
examined using Cochran’s Q and the I
2 statistic [7]. The first
step in getting the combined mortality rate was done by obtaining
the number of deaths in individual studies. Most studies, that used
Kaplan-Meier methods, summarized the number of deaths and
the number in the risk set at each time point. For the few studies
for which we did not have these data available, methods described
in Parmar et al [8] and Whitehead & Whitehead [9] were used to
estimate the number of deaths and lost to follow-up. If there was
an evidence of variation between the studies, a random effects
model was used to estimate the combined mortality rate and
corresponding 95% confidence interval using standard methods
[10], otherwise a fixed-effects model was used. The meta-analysis
was summarized graphically using a Forest Plot. An analysis of
publication bias was also performed using a Funnel Plot and
Kendall’s test [11]. All analyses were done using S-plus 8.1
(TIBCO, Palo Alto, CA) and StatsDirect (UK). A sensitivity
analysis was done to estimate the bounds for the combined
mortality rate. All lost-to-follow-up, for the upper bound were
assumed to be dead (worst case scenario), and were assumed to be
living for the lower bound (best case scenario). A DerSimonian &
Liard estimate of mortality probability and corresponding 95% CI
were calculated [10].
Our secondary outcomes of interest included reported causes of
mortality and reported independent risk factors associated with
early mortality in multivariate analysis. We reported these risk
factor associations as hazard ratios or odds ratios as appropriate.
Lastly, we assessed the quality of studies by evaluating the chance
of ascertainment bias, which was calculated from two parameters:
loss-to-follow-up reported and method for ascertainment of
mortality reported. One point each was assigned for the above
two parameters. Thus, the scoring was such that: 2 points
indicated a low chance of ascertainment bias, 1 point indicated
moderate chance of ascertainment bias and 0 points indicated
high chance of ascertainment bias. We also assessed reporting of
HIV-RNA plasma concentration, use of prophylaxis for opportu-
nistic infections, adherence, control of confounding factors, and
accounting for loss-to-follow-up. Confounder control in the
included studies was considered to be adequate if multivariate
analysis was performed (e.g., Cox proportional hazards or logistic
regression to identify independent risk factors).
Results
Of 875 articles, 187 studies received full text review, of which 50
met our inclusion criteria {figure 1}. Of 50 included studies, 38
(76%) were from SSA, five (10%) were multi-regional (Africa, Asia,
South and Central America and the Caribbean), five (10%) were
from Asia and two (4%) were from the Americas (South and
Central Americas and the Caribbean) {table 1}. Most studies
(n=47) were published between the years 2005–2010, with the
largest number of publications being in 2008 (n=17).
Base-line characteristics
The majority (48%) of studies were in an urban setting, 18%
were in rural, 24% were in a mixed setting and 10% were
unknown {table S2}. Cohort size ranged from 109–81,821
persons. The proportion of females ranged from 2%–81%. Thirty-
four (68%) studies reported a median baseline CD4 cell count that
ranged from 11–192 cells/mm
3; median CD4 cell count was
lowest from the Asian studies (11–41 cells/mm
3). Fourteen (28%)
studies reported median baseline log HIV-RNA concentrations
that ranged from 4.6–5.7 log copies/ml. Median follow-up was
reported by 42 (84%) studies and ranged from 3–55 months. Forty
(80%) studies reported loss-to-follow-up, which overall ranged
from 0.3%–27%. Lost-to-follow-up was highest in SSA.
Mortality characteristics
Mortality at the end of follow-up varied by region and ranged
from 2.6%–29.7%, with the lowest reported from the South
American cohort of a multi-regional study and highest from SSA.
Forty (80%) studies reported on 12 month post-ART initiation
mortality however method of mortality reporting varied {table 1}.
The overall pooled estimate of mortality at 12-months post-ART
initiation was 0.14 (95% CI 0.10–0.20) but varied substantially by
region. The highest mortality estimate was in SSA 0.17 (95% CI
0.11–0.24) followed by Asia 0.11 (95% CI 0.10–0.13); the
Americas 0.07 (0.007–0.20); and multiregional 0.08 (95% CI
0.06–0.10) {figure 2}. A sensitivity analysis to assess the best case
scenario where all loss-to-follow-up were assumed to have survived
versus the worst case scenario where all loss-to-follow-up were
assumed to have died is shown in figure 3. The majority of deaths
were found to have occurred in the first three months after ART
initiation {table S2}.
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Thirty-one (62%) studies [SSA, n=24; Asia, n=2; Americas,
n=1; Multi-region, n=4] assessed independent risk factors
associated with early mortality {table 2}. We did not report
one of the 31studies due to insufficient data (strength of association
of independent risk factors in terms of hazard or odds ratios were
not reported) [12]. Factors assessed and reported to have
independent association were: low baseline CD4 cell count
(n=23); advanced World Health Organization (WHO) clinical
stage (n=20); low body mass index (BMI) (n=11); male sex
(n=9); anemia (n=8); age (n=5); weight (n=4); ART adherence
(n=3); cotrimoxazole use (n=2); total lymphocyte count (n=2);
high HIV RNA (n=1); adherence to visits (n=1); calendar year
(n=1); any education (n=1); renal function (n=1); Kaposi’s
sarcoma (n=1); hospital type (n=1); ART regimen (n=1);
tuberculosis (TB) clinic on site (n=1); platelet count (n=1); and
fluconazole use (n=1) {table S3}. When using standardized
definitions across studies as shown in table 2, pre-ART CD4 cell
count ,50 cells/mm
3, male sex, WHO clinical stage 4, low
BMI,18.5, hemoglobin ,8 g/dL, age .40 years, and pre-ART
HIV RNA.5 log copies/ml carried the greatest risks for early
mortality.
Figure 1. Study selection process and reasons for exclusion of studies. Flow chart constructed using the PRISMA guidelines (Moher D,
Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA
Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097).
doi:10.1371/journal.pone.0028691.g001
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1 and reported mortality and probability of survival at 12 months post-ART initiation by
region.
Study Year Region
2 Country n (%F)
Loss to Follow-
up, n (%)
Incidence
of Death
Probability
of Survival
Proportion
of Death
3
Alemu [26] 2010 SSA Ethiopia 272 (57) - - - 9.6%
Sanne [27] 2009 SSA South Africa 7536 (67) - - 0.91–0.99
4 -
Abaasa [28] 2008 SSA Uganda 897 (75) 147 (16) 12.0/100py - 18.0%
Banda [29] 2008 SSA Malawi 81821 (61) 7753 (10) - 0.61 -
Bisson [30] 2008 SSA Botswana 410 (60) 22 (5) - 0.83 -
Boulle [31] 2008 SSA South Africa 12587 (70) 838 (7) - 0.85 7.5%
Bussmann [32] 2008 SSA Botswana 633 (60) 102 (16) - 0.83 -
Hoffmann [33] 2008 SSA South Africa 853 (2) - - - 4.0%
Johannessen [34] 2008 SSA Tanzania 320 (70) 31 (10) - 0.71 -
Laurent [35] 2008 SSA Cameroon 169 (67) - - - 11.2%
MacPherson [36] 2008 SSA South Africa 1353 (67) 35 (3) 7.5/100py - -
Marrrazi [37] 2008 SSA Mozambique, Tanzania, and Malawi 3456 (60) 41 (1) 9.7/100py - 7.5%
Mulenga [38] 2008 SSA Zambia 25779 (60) - - - 8?1%
Mzileni [39] 2008 SSA South Africa 3073 (67) 434 (14) - - 6.5%
Toure [40] 2008 SSA Cote d’Ivoire 10211 (70) 1385 (14) - 0.77–0.94
5 -
Yu [24] 2008 SSA Malawi 2574 (-) - - 0.42, 0.82
6 -
Karcher [41] 2007 SSA Kenya 124 (81) 34 (27) - 0.85 -
Makombe [42] 2007 SSA Malawi 4580 (-) 511 (11) - 0.87 12.7%
Makombe [43] 2007 SSA Malawi 1022 (65) 40 (4) - 0.81 -
Bekker [44] 2006 SSA South Africa 1139(69) 33 (3) - - 5.0%-13.0%
7
Etard [45] 2006 SSA Senegal 404 (55) 16 (4) - 0.88 11.6%
Ferradini [46] 2006 SSA Malawi 1308 (64) 91 (7) - 0.81 -
Lawn [47] 2006 SSA South Africa 927 (72) 21 (2) - 0.91 -
Stringer [4] 2006 SSA Zambia 16198 (61) 3408 (21) - 0.82 -
Zachariah [48] 2006 SSA Malawi 1507 (66) 46 (3) - 0?87 11.7%
Bourgeois [49] 2005 SSA Cameroon 109 (66) 3 (3) - 0.92 -
Wester [12] 2005 SSA Botswana 153 (59) - (8) - 0.85 14.4%
Coetzee [50] 2004 SSA South Africa 287 (70) 1 (0) - 0.86 13.2%
Djomand [23] 2003 SSA Cote d’Ivoire 490 (40) - - 0.84 -
Weidle [51] 2002 SSA Uganda 476 (-) 114 (24) - 0.74 -
Ruan [52]
8 2010 Asia China 341 (46) 46 (14) - - 8.8%
Chasombat [53] 2009 Asia Thailand 58008 (48) 5130 (9) - 0.89 -
Morineau [54] 2009 Asia Cambodia 549 (53) not clear
9 11.3/100py - -
Ferradini [55] 2007 Asia Cambodia 416 (41) 7 (2) - 0.87 -
Corey [56] 2007 Americas Peru 564 (70) - - 0.97 -
Severe [3] 2005 Americas Haiti 910 (55) 71 (8) - 0.87 14.0%
O’Brien [57]
10 2010 Multi-regional Africa & Asia 3757 (66) 413 (11) - 0.89 9.0%
Tuboi [58] 2009 Multi-regional Latin America, Caribbean 5152 (35) 297 (6) - 0.92 -
Braitstein [5] 2006 Multi-regional Africa, South America & Asia 4810 (51) 727 (15) 2.7/100py 0.94, 0.98
11 -
Calmy [59] 2006 Multi-regional Africa, South America & Asia 6861 (61) 328 (5) - 0.90 -
F=female; PY=person years;
1Only studies reported mortality measurements at 12 months post-ART initiation were listed. See {table S2} for summaries of papers not listed here [19,60–68];
2SSA: Sub-Saharan Africa; Americas: South & Central America, Caribbean; Multi-regional: includes SSA, Asia and the Americas;
3Deaths expressed as percent of total population in the study;
4Probability of survival was only presented by CD4 cell count level: CD4,=50: 0.91, CD4 51–100: 0.97, CD4 101–200: 0.98, CD4.200: 0.99.
5Probability of survival was only presented by CD4 cell count level: CD4,=50: 0.77, CD4 51–100: 0.86, CD4 101–150: 0.91, CD4.150: 0.94.
6Probability of survival was only presented by TB status: with TB: 0.42, without TB: 0.82.
7Proportion was reported during each calendar year: 2002–’03: 13.0%, 2003–’04: 7.9%, 2004–’05: 5.0%;
8Assumed death and loss-to-follow-up were 12 month data since only 12-month assessment was mentioned.
9Loss to follow-up was reported but time was not given;
10Supplement table 3 was used to obtain data for adults only;
11Probabilities were reported in both active (0.94) and passive (0.98) follow-up groups.
doi:10.1371/journal.pone.0028691.t001
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Fourteen (28%) studies reported cause-specific mortality [SSA,
n=11; Asia, n=1; Americas, n=2] {table 3}. Most common
causes of death reported were TB accounting for 5%–44% of
deaths; advanced HIV 20%–37%; wasting 5%–53%; chronic
diarrhea 10%–25%; Cryptococcal meningitis 3%–18%; and
Kaposi’s sarcoma 3%–12%. Five (36%) of 14 studies reported a
specific method for ascertaining the cause of death, of which two
used verbal autopsy along with patient records. Most of the studies
reported the causes of deaths based on clinical diagnosis but not
microbiological confirmation.
Quality of studies
Most studies (92%) had low-to-moderate risk of ascertainment bias.
However, only a small proportion disclosed prophylaxis for opportu-
nistic infection (24%), or mentioned adherence (38%) {table S4}.
There was evidence of heterogeneity or reporting bias as assessed by a
funnel plot (Kendall’s tau was 0.4 with p-value=0.0046) {figure 4}.
Discussion
In our study, we carefully reviewed and summarized the
magnitude of early deaths occurring within the first 12 months
Figure 3. Sensitivity analyses for pooled regional estimates of mortality at 12 months by best case (all loss-to-follow-up assumed to
have survived) and worst case (all lost-to-follow-up assumed to have died) scenarios.
doi:10.1371/journal.pone.0028691.g003
Figure 2. Forest plot of estimates of mortality at 12 months by individual studies and pooled by region. Pooled estimates are summary
random effects estimates with 95% confidence intervals. Two studies were excluded as they did not provide appropriate data for pooling (Djomand
[23] and Yu [24]). The summary pooled estimate is 0.14 (95% CI 0.10–0.20). Test for heterogeneity by region was as follows [7]: Sub-Saharan Africa
Cochran Q=7691, p-value,0.0001 and I
2=99.84% (95% CI 99.8%–99.8%)- suggesting there is an evidence of heterogeneity among studies; Asia
Cochran Q=1.67; p=0.20– suggesting non-heterogeneous studies (I
2 cannot be estimated since only 2 studies); Americas Cochran Q=51.54;
p,0.0001 – suggesting there is evidence of heterogeneity (I
2 cannot be estimated since only 2 studies) and Multiregional: Cochran Q=90.7;
p,0.0001 and I
2=96.7% (95% CI 94.7%–98.7%) suggesting there is evidence of heterogeneity.
doi:10.1371/journal.pone.0028691.g002
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needed by healthcare providers, policy makers, program funders
alike to determine resource allocation and to optimize care and
treatment strategies for HIV in LMIC. More than three-quarters
of our included studies were from SSA. While this appears to
reiterate that SSA continues to bear a large portion of global HIV
burden, it also points to the relative lack of published data on early
mortality from LMIC outside of SSA.
An overall estimate of mortality 12 months post-ART initiation
was 14% with the highest probability being reported from SSA at
17%, followed by Asia at 11%, and the Americas at 7%. These
differences could represent differences in factors such incidence of
opportunistic infections, nutrition levels, socioeconomic levels and
disease stage of study participants. However, it is also likely that
some of the difference may be due to varying differences in
economic and health infrastructure across regions. Consistent with
this, Lawn et al have demonstrated an inverse ecologic relationship
between growth domestic product (GDP) per capita and mortality
proportion for 21 cohorts assessed [13]. However the specific
reasons for such differences between regions could not be
specifically teased out in our systematic review based on the
available reported data.
Among the studies that reported on deaths within the first year
of ART initiation, we observed that most deaths occurred within
the first 3 months of ART initiation. This reflects the advanced
stage of HIV disease of many participants in whom ART was
initiated and is evidenced by the finding that more than 50% of
included studies reported a median baseline CD4 cell count at or
below 150 cells/mm
3 and that the vast majority of patients had
advanced HIV disease stage as ascertained by WHO clinical
staging. It is clear from several published studies that starting ART
at a higher CD4 cell count will reduce morbidity and avert the
high mortality rates seen among patients with advanced HIV
disease [14,15]. For this reason, there has been a call for more
aggressive testing and treating of HIV-infected persons upon
identification of their HIV status irrespective of their CD4 cell
count or disease stage as several decision models suggest that this is
an optimal strategy to reduce HIV-associated morbidity and
mortality in LMIC [16]. However, the cost-effectiveness and
implementation of such a strategy remain unknown. Other
strategies to reduce early mortality are likely to include better
screening, prevention and management of opportunistic infections
such as TB, better pre-ART care, and retention of patients in HIV
programs. However, where to best focus limited financial
resources needs further evaluation. Irrespective of what strategies
are adopted, late presenters to care (HIV-infected patients with
CD4 cell counts less than 200 cells/mm
3) will remain an ongoing
reality. Therefore, understanding the risks of death and assessing
strategies to deal with early mortality in this vulnerable population
remain critical.
Only one-third of included studies reported causes of death and
the majority of these were from SSA. TB and wasting appeared to
be the most common causes of early mortality. It is unclear as to
what proportion of wasting in patients could be attributed to TB or
other opportunistic infections, but it is likely that TB has some
substantial contribution as an autopsy study in South Africa
identified TB as the most common cause of death in patients
receiving ART [17]. Approaches to reducing TB burden as a
contributor to early mortality are needed and will likely include
scaling up of TB prevention among HIV- positive adults seeking to
start ART, using novel rapid TB detection methods such as
Cepheid Gene Xpert MTB, and assessing the role of pre-emptive
TB therapy along with starting ART in those at highest risk of
early mortality, such as those with very advanced HIV disease.
The latter strategy is being assessed by the AIDS Clinical Trials
Group 5274 REMEMBER trial (NCT 1380080).
Table 2. Range of hazard and odds ratios of independent risk factors associated with early mortality by region.
Association Low BMI CD4(,50) WHO Stage 4 Hb (,8 g/dL)
Age ($40
years)
VL (.5l o g
copies/ml) Male Sex
n=5 n=13 n=8 n=4 n=1 n=1 n=9
Sub-Saharan Africa
Hazard ratio 1.93
1–2.92 1.64–5.90 1.99–5.13
2 3.10–9.20 - - 1.52–2.22
Odds ratio 2.10
3,4–6.00
3,5 2.20–2.93 2.10
3 2.10
3 - 2.00
3 -
Asia
Hazard ratio 2.47
3,6 2.43
3 1.86
3 - 1.24
3 - 1.96
3
Americas
Hazard ratio - 1.60
3 --- - -
Muti-regional
Hazard ratio - 1.27
7–3.34
8 3.86
3 2.62
3 - - 1.75
3
Factors included in the table are from the studies that reported risk factors having independent association with early mortality in multivariate analysis. We used most
commonly used cutoff values to summarize findings across different studies, therefore factors found associated with early mortality using other definitions were not
presented in this table. See {table S3} for complete details. BMI=Body Mass Index, all BMI values are in kg/m
2 and ,18.5 unless mentioned otherwise; CD4=CD4 cell
count, all CD4 counts are ,50 cells/mm
3 unless mentioned otherwise; WHO stage 4=World Health Organization clinical stage 4; Hb=Hemoglobin, hemoglobin
values are ,8 gm/dL; Age is .40 years unless mentioned otherwise; VL=Viral Load;
1BMI,18.5 vs BMI.25;
2Using the real-case model in Alemu 2010 paper [26];
3Reported by only one study;
4For BMI in the range 17–18.4;
5For BMI,15.9;
6Hazard ratio 2.47 for BMI,17 vs BMI.=18.5;
7CD4 50 vs CD4 100;
8CD4,25 vs CD4.=50.
doi:10.1371/journal.pone.0028691.t002
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Study (Year)
Total
Deaths,
n( % )
Known
Causes,
n( % ) Causes of Death, n (%)
Methods
to
Ascertain
Deaths
1
TB
Advanced
HIV Wasting CM KS
Chronic
Diarrhea Others
Sub-Saharan
Africa
Bussmann [32]
(2008)
120 (19.0) - 8 (6.7) 41 (34.2)
2 See
footnote
2
--- - a , b
3
Laurent [35]
(2008)
19 (11.2) 19 (100.0) 1 (5.3) 6 (31.6) 1 (5.3) - - - Poor general health 6 (31.6); hepatic
carcinoma 1 (5.3); hepatitis & pancreatitis
1 (5.3); persistent FUO 1 (5.3); malaria
1 (5.3); pulmonary infection 1 (5.3)
NS
MacPherson
[36] (2008)
124 (9.1) 106 (85.5) 47 (44.3) - - 3 (2.8) 3 (2.8) 26 (24.5) Carcinoma 4 (3.8); cerebral space occupying
lesion 4 (3.8); septicemia 4 (3.8); hepatic
failure 3 (2.8); obstetric 2 (1.9); bacterial
meningitis 2 (1.9); congestive cardiac failure 2
(1.9); pneumonia 2 (1.9); HIV encephalopathy
1 (0.9); diabetic ketoacidosis 1 (0.9); renal
failure 1 (0.9); upper GI bleed 1 (0.9)
NS
Marazzi [37]
(2008)
260 (7.5) 122 (46.9) 23 (18.9) - - - - - Malaria 39 (32.0); anemia 35 (28.7) NS
Mzileni [39]
(2008)
205 (7.8) 204 (99.5) 42 (20.6) 76 (37.3) - 18 (8.8) 11 (5.4) 25 (12.3) Bacterial pneumonia/PCP 12 (5.9);
lactic acidosis 12 (5.9); lymphoma
6 (2.9); hepatitis 6 (2.9); stroke 3 (1.5)
NS
Karcher [41]
(2007)
15 (12.1) 11 (73.3) 4 (36.4) - 1 (9.1) 2 (18.2) 1 (9.1) - PCP 2 (18.2); gastroenteritis 1 (9.1) NS
Etard [45]
(2006)
93 (23.0) 80 (86.0) 17 (21.3) - - - 2 (2.5) - Neurological disorders 17 (21.3);
septicemia 17 (21.3); gastro-intestinal
infections 10 (12.5); respiratory 6 (7.5);
hepatitis 5 (6.3); metabolic disorder 3
(3.8); other 3 (3.8)
a, b
Zachariah
[48] (2006)
190 (12.6) 105 (55.3) 10 (9.5) - 6 (5.7) 7 (6.7) 13 (12.4) 10 (9.5) Oral Candidiasis 26 (24.8); esophageal
Candidiasis 15 (14.3); severe bacterial
pneumonia 12 (11.4); chronic fever 4
(3.8); PCP 2 (1.9)
a
Bourgeois
[49] (2005)
9 (8.3) 9 (100.0) 1 (11.1) 2 (22.2) 1 (11.1) - - - Poor general health 2 (22.2); FUO 1
(11.1); hepatitis & pancreatitis 1 (11.1);
hepatic carcinoma 1 (11.1)
NS
Wester [12]
(2005)
24 (15.7) 20 (83.3) 4 (20.0) 4 (20.0) 2 (10.0) 1 (5.0) 2 (10.0) - Hepatotoxicity 2 (10.0); anemia 1(5.0);
lymphoma 1(5.0); renal failure 1(5.0);
suicide 1(5.0); traditional medicine
toxicity 1(5.0)
c
Coetzee [50]
(2004)
38 (13.2) 38 (100.0) 3 (7.9) 20 (25.6) - - 3 (7.9)
4 - Treatment discontinuation/poor
adherence 6 (15.8); not attributed
to HIV 2 (5.3); CMV colitis1 (2.6)
NS
Asia
Chasombat [53]
5
(2009)
7637 (13.2) 5616 (73.5) - - - - - - - NS
Americas
Corey [56]
(2007)
16 (2.8) 13 (81.3) 2 (15.4) - 4 (30.8) 1 (7.7) 1 (7.7) - Pulmonary insufficiency 2 (15.4);
lymphoma 1 (7.7); CMV 1 (7.7);
sepsis 1 (7.7)
a
Severe [3]
(2005)
127 (14.0) 104 (81.9) 20 (19.2) - 55 (52.9) - - - Bacterial pneumonia 6 (5.8); Toxoplasmosis 5
(4.8); malignancy 4 (3.8); Cryptosporidiosis 4
(3.8); sepsis 4 (3.8); congestive heart failure 3
(2.9); trauma 3 (2.9)
NS
TB=Tuberculosis; CM=Cryptococcal Meningitis; KS=Kaposi’s Sarcoma; FUO=Fever of Unknown Origin; PCP=Pneumocystis Carinii Pneumonia;
CMV=Cytomegalovirus;
1a: Clinical record; b: Verbal autopsy; c: Active ascertainment but unspecified; NS: not specified;
2Advanced HIV and wasting were reported together;
3Information available in 71 deaths;
4Probable KS;
5Deaths were only recorded as due to AIDS or unknown. All deaths with known causes (n=5616) were due to AIDS.
doi:10.1371/journal.pone.0028691.t003
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age and male sex. Interestingly, older age has been associated with
later presentation, diagnostic delays, as well as with immune
senescence and poorer CD4 immune reconstitution, which may in
part explain the findings [18,19].The observation that males were
in general more likely to die early in the course of therapy than
females may be because of discrepancies in healthcare seeking
behavior between the sexes or poorer adherence in men or due to
biological differences in ART response, but these differences need
to be further examined as prior studies have found mixed evidence
for sex differences in HIV disease progression, adherence and HIV
treatment outcomes [20–22].
While several studies have alluded to the underlying association
between early mortality and poor nutrition, few studies have
directly assessed this association. Most studies that have reported
on nutrition have used BMI, body weight or hemoglobin levels as
proxy markers of nutrition. While these are frequently used
correlates of nutrition, their utility is confounded by the existence
of co-morbidities in patients with HIV that may influence the body
weight, BMI or hemoglobin levels. For example, anemia can be
due to non-nutritional causes such as anemia of chronic disease
due to HIV infection and likely represents a large proportion of
the patients who were defined as having anemia in the included
studies. However, iron deficiency anemia or anemia due to other
micronutrient deficiencies were not ascertained in any of the
studies, therefore the role of malnutrition-induced anemia
contributing to early mortality remains inadequately assessed.
Our study had a few limitations. Like any systematic review,
there is the possibility of incomplete retrieval or abstraction of
data; however, we used three independent reviewers to try and
best address this. Furthermore, we did not obtain raw data from
study investigators for pooled estimation of mortality; however, we
used only those studies from which appropriate Kaplan-Meier
data could be extracted using published methods. There was also
substantial heterogeneity and/or reporting bias among the studies,
so the pooled estimates have to be understood in that context.
Despite this heterogeneity, we felt it was important to pool the
existing data to estimate mortality probability at 12 months as
these data provide a more robust estimate than any single study
alone. Furthermore, we performed a sensitivity analysis to assess
best and worst case scenarios for mortality estimates based on
assumptions made for those who were loss-to-follow-up. In
addition, we could not pool risk factors or the reported causes of
death such as low CD4 cell count or TB, respectively, as there
were insufficient data included in the published studies to perform
this.
In conclusion, more studies are needed to report on factors that
affect early mortality in LMICs outside of SSA- in particular, high
burden regions like South and Southeast Asia and Latin America.
Future studies also need to focus on rural populations, more
specific nutritional assessment and improved ascertainment of
causes of death. Lastly, assessments of interventions directed at late
presenters with advanced HIV are needed, as even with novel
approaches such as HIV test-and-treat strategies, there will likely
Figure 4. Funnel plot. The funnel plot assesses the hypothesis that the relationship between probability of death and study size, measured by
standard error, is independent. This was tested using a Kendall’s tau, which was estimated to be 0.4 with p-value=0.0046, suggesting there is
evidence of asymmetry. Although the presence of publication bias is a common explanation to an asymmetric funnel plot, data presented here are
observational data without any intervention so the funnel plot asymmetry could also be due to heterogeneity in the data [25].
doi:10.1371/journal.pone.0028691.g004
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disease and remain at high risk for early mortality despite ART
initiation.
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